This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I62 (Other nontraumatic intracranial haemorrhage) | Special Copayment Reduction: V191 (Special copayment reduction for cerebrovascular disease: 5% copayment for up to 30 days from the registration date) |
| B. Synonyms | Nontraumatic subdural hematoma, nontraumatic epidural hematoma, nontraumatic intracranial hemorrhage |
| C. Adult onset | Chronic subdural hematoma has a high incidence in older adults and, with increasing use of anticoagulants and antiplatelet agents, is emerging as an important neurosurgical problem in the elderly population. |
| 1. History | Beginning with Virchow's description of subdural hematoma in the 17th century, diagnosis and patterns of occurrence have changed with the introduction of CT and the widespread use of anticoagulant therapy. |
| 2. Causes | Anticoagulant and antiplatelet use, coagulation disorders, dural arteriovenous fistula, low cerebrospinal fluid pressure, and tumors are the main nontraumatic causes. |
| 3. Genetics | Coagulation factor gene variants (F8, F9, VWF, etc.) and genes related to platelet dysfunction contribute to bleeding predisposition. |
| 4. General epidemiology | The incidence of chronic subdural hematoma is 1.7–20.6 per 100,000 population per year, and it is increasing with greater anticoagulant use and population aging. |
| 5. Pathophysiology | Bleeding that begins with bridging vein rupture or vascular invasion gradually expands into a hematoma through osmotic pressure differences, exudation from neovessels, and enhanced local fibrinolysis. |
| 6. Symptoms | Headache, cognitive decline, gait disturbance, hemiparesis, speech disturbance, and decreased consciousness appear gradually or suddenly. |
| 7. Signs | Hemiparesis, decreased consciousness, pupillary abnormalities, and hyperreflexia occur, and the chronic form may show dementia-like signs. |
| 8. Screening | Regular neurological assessment and risk factor monitoring are recommended in patients taking anticoagulants. |
| 9. Diagnosis | CT is the first-line diagnostic test, and MRI provides detailed evaluation of subacute and chronic hematomas and causative vascular lesions. |
| 10. Treatment | Small asymptomatic hematomas are observed, and in cases of neurological abnormality or large hematoma, the hematoma is removed by burr-hole drainage or craniotomy. |
| 11. Prognosis | Most function recovers after surgery, but the recurrence rate is about 10–20%, and the risk of recurrence is high in older adults and anticoagulant users. |
| 12. Prevention | Appropriate anticoagulant management, fall prevention, and stopping alcohol abuse are the main preventive strategies. |
| 13. References | Adhiyaman V, et al. Chronic subdural haematoma in the elderly. Postgrad Med J. 2002 … and 9 other papers |
Other nontraumatic intracranial haemorrhage (I62) is a category in the ICD-10 classification covering nontraumatic intracranial hemorrhages not classified as intracerebral hemorrhage (I61) or subarachnoid hemorrhage (I60), and mainly includes nontraumatic subdural hematoma (SDH) and nontraumatic epidural hematoma (EDH). The clinical significance of subdural hematoma was first recognized by Johann Jakob Wepfer in the 17th century and Rudolf Virchow in the 19th century. Virchow (1857) named subdural hematoma 'Pachymeningitis interna hemorrhagica' and described that neovascular membrane formation on the inner surface of the dura contributes to hematoma expansion.
In the early 20th century, drainage of subdural hematoma through cranial trephination was first attempted, and in 1925 Walter Dandy successfully treated subdural hematoma using various neurosurgical approaches. The clinical introduction of CT in the 1970s brought revolutionary change to the diagnosis of subdural hematoma. By providing imaging findings that clearly distinguish acute, subacute, and chronic subdural hematoma (hyperdense, isodense, and hypodense, respectively), CT dramatically increased the diagnostic rate of chronic subdural hematoma, which had previously been easy to miss clinically. In particular, as understanding deepened of the nontraumatic mechanisms of chronic subdural hematoma, which occurs in older adults even after minor head trauma, the concept of nontraumatic subdural hematoma classified under code I62 even when a history of trauma is unclear or absent was established.
Since the 2000s, the incidence of nontraumatic subdural hematoma has continued to rise as the surge in the population using anticoagulants (warfarin, DOACs) and antiplatelet agents has coincided with population aging. In response, along with the standard treatment of subdural hematoma (burr-hole drainage), new treatment options (middle meningeal artery embolization, drug therapy such as dexamethasone) are being studied clinically. Numerous randomized controlled trials, such as the 2021 DAMS study (Dexamethasone for Adult Subdural), are contributing to the development of treatment guidelines for subdural hematoma.
The causes of nontraumatic intracranial hemorrhage (I62) can be understood by dividing them into subdural and epidural hematoma. The most important causes of nontraumatic subdural hematoma are coagulopathy and the use of anticoagulant and antiplatelet agents. In patients taking warfarin, heparin, DOACs (dabigatran, rivaroxaban, apixaban, etc.), aspirin, clopidogrel, etc., bridging vein rupture easily occurs even with minor head impact, and spontaneous absorption of the hematoma is delayed, so it tends to progress to chronic subdural hematoma.
Coagulopathy caused by hematologic diseases is also an important cause. Hemophilia (hemophilia A/B), von Willebrand disease, coagulation factor deficiency due to liver cirrhosis, thrombocytopenia (immune thrombocytopenic purpura, thrombotic microangiopathy, etc.), and disseminated intravascular coagulation (DIC) act as predisposing factors for nontraumatic subdural hematoma. Dural arteriovenous fistula can cause leakage of blood into the subdural space through venous hypertension.
Intracranial hypotension is also a not uncommon cause of nontraumatic subdural hematoma. Spontaneous intracranial hypotension is caused by cerebrospinal fluid (CSF) leakage, and brain sag widens the subdural space, stretching and rupturing bridging veins and producing subdural hematoma. Cases in which headache worsens after lumbar puncture and subdural hematoma develops also fall under this mechanism. In addition, tumors of the brain surface (brain metastases, meningioma), brain abscess, and brain atrophy (enlargement of the subdural space due to reduced brain parenchyma) are also factors promoting subdural hematoma. Nontraumatic epidural hematoma is rare but can be caused by coagulopathy, dural arteriovenous malformation, or dural or bone tumor infiltration.
The genetic contribution to nontraumatic intracranial hemorrhage is mainly associated with hereditary diseases that cause coagulopathy. Hemophilia A is a deficiency of coagulation factor VIII caused by variants in the F8 gene (X-linked), and the risk of spontaneous intracranial hemorrhage is greatly increased. Hemophilia B is a factor IX deficiency caused by F9 gene variants, and intracranial hemorrhage is the most lethal complication of hemophilia. Von Willebrand disease is caused by VWF gene variants, and the severe form (Type 3) carries a risk of spontaneous intracranial hemorrhage.
Hereditary diseases causing platelet dysfunction are also involved. In Glanzmann's thrombasthenia, variants in the ITGA2B or ITGB3 genes cause GPIIb/IIIa deficiency, resulting in a severe bleeding tendency, and intracranial hemorrhage rarely occurs. Bernard-Soulier syndrome is characterized by giant platelets and thrombocytopenia due to variants in the GP1BA, GP1BB, and GP9 genes. VKORC1 and CYP2C9 gene polymorphisms affect warfarin metabolism, so an excessive anticoagulant effect can occur even at the same warfarin dose, indirectly contributing to bleeding risk.
The genetic background of dural arteriovenous fistula (DAVF) has not been fully elucidated, but an increased risk of DAVF is known in hereditary hemorrhagic telangiectasia (HHT), and HHT is associated with variants in the ENG (HHT1), ACVRL1 (HHT2), and SMAD4 (JP-HHT) genes. Variants in connective tissue disease-related genes (COL1A1, COL5A1, etc.) have also been reported in some cases of spontaneous intracranial hypotension, suggesting a genetic basis for susceptibility to CSF leakage.
The epidemiology of nontraumatic intracranial hemorrhage (I62) is described with a focus on subdural hematoma. The annual incidence of chronic subdural hematoma (CSDH) varies between studies at about 1.7–20.6 per 100,000 population, but it continues to increase due to greater anticoagulant use and population aging. Some reports indicate an annual incidence of about 58 per 100,000 in people in their 70s and up to 127 in those aged 80 and older. The sex distribution is 2–3 times higher in men, which is associated with sex differences in alcohol consumption, anticoagulant use, and frequency of head trauma.
The incidence of subdural hematoma in patients taking anticoagulants is known to be 3–8 times higher than in the general population, and it is reported to be somewhat lower in DOAC users than in warfarin users. In Korea as well, the number of CSDH hospitalizations is steadily increasing with population aging and greater antithrombotic use. Nontraumatic acute subdural hematoma is caused by dural arteriovenous fistula, brain tumors, and hematologic diseases, and its incidence is much lower than that of traumatic subdural hematoma. Nontraumatic epidural hematoma is a very rare condition accounting for 0.5–4% of all epidural hematomas and is mainly caused by coagulopathy or tumor infiltration.
Regarding regional differences, traumatic subdural hematoma is more common in developing countries, whereas the proportion of anticoagulant-related nontraumatic subdural hematoma is relatively higher in developed countries. Low platelet count, liver cirrhosis, and chronic alcoholism are independent risk factors for nontraumatic subdural hematoma. In alcohol abusers, coagulopathy due to impaired liver function together with enlargement of the subdural space due to brain atrophy markedly increases the risk of subdural hematoma.
The pathophysiology of nontraumatic subdural hematoma can be broadly divided into two stages. In the initial stage, a small amount of blood enters the subdural space through minor or unrecognized vascular injury (microrupture of bridging veins, injury to dural neovessels). If this blood is not spontaneously absorbed because of coagulopathy or anticoagulant effects, a pseudocapsule consisting of the outer membrane and inner membrane of the hematoma begins to form. The outer membrane is richly supplied with neovessels induced by angiogenic stimuli such as VEGF (vascular endothelial growth factor) within the hematoma, and these fragile neovessels bleed repeatedly, gradually enlarging the hematoma.
The key mechanisms of hematoma expansion are osmotic pressure differences and enhanced local fibrinolysis. Due to protein degradation products within the hematoma and the semipermeability of the hematoma capsule, an osmotic gradient forms, plasma fluid flows into the hematoma, and the hematoma volume increases. At the same time, local fibrinolysis by tissue plasminogen activator (tPA) and urokinase (uPA) is enhanced within the hematoma, dissolving newly formed clots and increasing the risk of rebleeding. These mechanisms act together to slowly enlarge the hematoma over weeks to months.
In nontraumatic subdural hematoma due to intracranial hypotension, the space between the brain and skull (subdural space) enlarges, and bridging veins are excessively stretched and rupture. Subdural hematoma due to dural arteriovenous fistula is understood to result from venous hypertension caused by an abnormal arteriovenous shunt that induces rupture of subdural veins. When the hematoma becomes large enough, it compresses the brain parenchyma, leading to midline shift, brain herniation, and increased intracranial pressure, which are the direct causes of worsening neurological symptoms.
The symptoms of nontraumatic intracranial hemorrhage vary according to the type (acute, subacute, chronic), location (subdural, epidural), size of the hematoma, and degree of brain compression. Chronic subdural hematoma (CSDH) is the most common subtype and is characterized by symptoms that develop slowly over weeks to months. The most common symptom is headache (about 75–90%), usually dull and persistent regardless of postural changes. Cognitive decline and memory impairment progress slowly and are often confused with dementia, so in older adults with unexplained cognitive decline, intracranial hematoma must always be ruled out.
Hemiparesis or hemibody weakness, speech disturbance (language or articulation disorder), gait disturbance, and seizures also occur when the hematoma compresses the cerebral cortex or motor areas. Symptoms are often intermittent or fluctuating and may be confused with transient ischemic attack (TIA) or cerebral infarction. Decreased consciousness occurs when the hematoma progresses and brain herniation develops or when acute bleeding is superimposed, a situation requiring emergency treatment. In nontraumatic acute subdural hematoma, symptoms appear abruptly, and with a large amount of bleeding the patient can become comatose within hours.
In subdural hematoma due to intracranial hypotension, orthostatic headache (worse when standing, better when lying down) is characteristic and may be accompanied by nausea, vomiting, neck pain, tinnitus, and diplopia. In subdural hematoma related to dural arteriovenous fistula, pulsatile tinnitus and visual disturbance due to increased intraocular pressure may precede it. Subdural hematoma due to hematologic disease is often accompanied by a systemic bleeding tendency such as cutaneous petechiae, bruising, and gum bleeding, which helps in differentiating the cause.
The main signs suggesting nontraumatic subdural hematoma on physical and neurological examination vary according to the size of the hematoma and the direction of compression. Initially, neurological abnormalities may be minimal, and especially in chronic subdural hematoma, often only nonspecific signs such as mild cognitive decline, gait instability, and slowed speech appear. Because of this, it is sometimes misdiagnosed as dementia, normal pressure hydrocephalus, or depression.
As the hematoma progresses, contralateral hemiparesis appears, and weakness predominantly of the upper limb is prominent especially when the cortical motor area is compressed. When brain herniation due to subdural hematoma begins, the Kernohan phenomenon (pupillary dilation and paralysis contralateral to the hematoma) may appear, making the initial evaluation difficult. Ipsilateral pupillary dilation (uncal herniation) is a sign of oculomotor nerve compression and indicates a neurosurgical emergency requiring prompt decompression. With frontal lobe compression, frontal lobe syndrome such as personality change, apathy, decreased concentration, and executive dysfunction may be observed, which is often difficult to distinguish from dementia in elderly patients.
The Cushing reflex, with elevated blood pressure accompanied by bradycardia, indicates a severe rise in intracranial pressure and requires immediate intervention. In bilateral subdural hematoma, decreased consciousness is more prominent, and bilateral lower limb weakness, urinary incontinence, and cognitive decline require differentiation from normal pressure hydrocephalus. Papilledema on funduscopic examination appears when intracranial pressure has been chronically elevated, suggesting a relatively advanced subdural hematoma.
General population screening for nontraumatic intracranial hemorrhage is not recommended, but clinical surveillance of high-risk groups is important. In patients taking anticoagulants or antiplatelet agents, immediate head CT is recommended when new neurological symptoms (headache, cognitive decline, hemiparesis) develop. In this patient group, the possibility of subdural hematoma should always be kept in mind even with mild symptoms. In particular, advanced age, brain atrophy, a history of falls, and excessive anticoagulation (INR above the therapeutic range) are a high-risk combination.
In patients with hemophilia or other congenital coagulation disorders, head CT should be considered after head trauma regardless of symptoms. In patients diagnosed with intracranial hypotension of unknown cause (spontaneous intracranial hypotension syndrome), the presence of accompanying subdural hematoma is periodically checked by brain MRI. In patients with liver cirrhosis, coagulation function (PT/INR, platelet count) is evaluated regularly, and if abnormalities are found, high-risk procedures and activities with a risk of trauma are minimized after correction. In connective tissue diseases at high risk of spontaneous intracranial hypotension (Marfan syndrome, Ehlers-Danlos syndrome), regular neurological assessment and brain MRI are considered.
In patients with suspected dural arteriovenous fistula (DAVF) (pulsatile tinnitus, ocular symptoms, unexplained headache), vascular evaluation by MRI/MRA or DSA is performed to detect DAVFs at high risk of bleeding (cortical venous drainage) early and to consider preventive treatment.
The diagnosis of nontraumatic intracranial hemorrhage begins with non-contrast head CT. CT can clearly distinguish acute subdural hematoma (crescent-shaped hyperdense lesion), subacute subdural hematoma (isodense or mixed density), and chronic subdural hematoma (hypodense or mixed density), and can rapidly assess the degree of midline shift and brain compression. Isodense subacute subdural hematoma may be difficult to diagnose on CT, so MRI is additionally performed when clinical suspicion is high.
MRI, with soft tissue resolution superior to CT, evaluates subacute and chronic subdural hematomas more accurately and is advantageous for diagnosing complex patterns such as bilateral hematomas, multilayered hematomas, and rebleeding within the hematoma. FLAIR and GRE (or SWI) sequences help detect subtle hematomas or hemosiderin deposition. In subdural hematoma due to intracranial hypotension, characteristic findings such as brain sag, dural enhancement, and reduced CSF spaces can be identified on MRI. When a vascular cause such as dural arteriovenous fistula is suspected, the vascular anatomy is evaluated with MRA, CTA, or DSA.
Blood tests evaluate bleeding predisposition by measuring the coagulation profile (PT/INR, aPTT, platelet count, platelet function tests), CBC, liver function tests, and anticoagulant blood levels (if needed). When spontaneous intracranial hypotension is suspected, the site of CSF leakage is identified by direct measurement of CSF pressure (normal <60 mmH₂O), epidural CSF leakage on spinal MRI, radionuclide cisternography, and CT myelography. When a causative vascular malformation within the hematoma is suspected, pathologic confirmation by intraoperative biopsy helps with the differential diagnosis.
Treatment of nontraumatic intracranial hemorrhage is decided by considering the size of the hematoma, the severity of symptoms, and the patient's general condition. When symptoms are absent or mild, hematoma thickness is less than 10mm, and midline shift is less than 5mm, conservative treatment (anticoagulant reversal, correction of the underlying cause) with imaging follow-up can be performed. However, surgical treatment is recommended when neurological symptoms are present or the hematoma progresses.
The standard surgical treatment for chronic subdural hematoma is burr-hole drainage. In this method, one or two small holes are made in the skull and the hematoma is drained; because it can be performed under local anesthesia, it is applicable even in elderly patients at high risk from general anesthesia. Closed irrigation, in which a drain is kept for 24–48 hours after surgery, is known to be effective in preventing hematoma recurrence. For acute or mixed subdural hematoma, hematomas difficult to drain because of thick septa, or recurrent hematomas, direct hematoma removal by craniotomy may be needed.
Recently, middle meningeal artery embolization (MMAE) has attracted attention as an endovascular treatment option for preventing recurrence of chronic subdural hematoma. It works by blocking the vascular supply of the hematoma capsule to suppress rebleeding; early studies showed outcomes similar to surgical treatment, and large randomized controlled trials are currently under way. In anticoagulant-related subdural hematoma, anticoagulant reversal (4F-PCC, idarucizumab, andexanet alfa, etc.) is needed as emergency treatment, and the timing of resuming anticoagulants after surgery is decided by individually assessing the risk of thromboembolism and the risk of rebleeding. In subdural hematoma due to intracranial hypotension, blocking the CSF leak with an epidural blood patch is the definitive treatment.
Surgical outcomes of nontraumatic subdural hematoma are generally good. In chronic subdural hematoma, the rate of neurological recovery after burr-hole drainage reaches about 70–80%, and mortality is reported at 0–8%. However, the considerably high recurrence rate of about 10–20% is an important problem. The main risk factors for recurrence are advanced age, continued anticoagulant use, antiplatelet use, bilateral hematoma, incomplete drainage, and rebleeding within the hematoma. Recurrence requires reoperation, and repeated recurrence carries a poorer prognosis.
Acute nontraumatic subdural hematoma often forms rapidly with severe brain compression, so its prognosis is relatively poor. Initial GCS, pupillary response, hematoma thickness, degree of midline shift, and age are the main determinants of prognosis. If special causes of nontraumatic subdural hematoma (dural arteriovenous fistula, intracranial hypotension) are not corrected, the risk of recurrence is high, so treatment of the underlying cause is essential. Intracranial hemorrhage due to congenital coagulation disorders such as hemophilia requires coagulation factor replacement therapy combined with surgery, and treatment at a medical institution with a specialized coagulation support system is ideal.
In the long-term prognosis, recovery of cognitive function occurs gradually over weeks to months after hematoma removal. In chronic subdural hematoma, complete recovery is possible in most cases when it is detected and treated early, but recovery may be incomplete when the hematoma went undetected for a long time and neurological damage progressed. Recurrence of the hematoma is checked with follow-up CT after surgery, and if residual hematoma is present, it is common to follow its spontaneous absorption over several months, even if small.
The key to preventing nontraumatic intracranial hemorrhage is managing the major risk factors. In patients taking anticoagulants, the INR is kept within the therapeutic range, and if an excessive anticoagulant effect (INR above 3) persists, dose adjustment or change of the drug is considered. Switching from warfarin to a DOAC can partly lower the risk of intracranial hemorrhage. Because combined use of antiplatelet agents and anticoagulants markedly increases bleeding risk, it is used cautiously only when there is a clear indication.
Fall prevention is particularly important in elderly patients taking anticoagulants. Removing fall hazards in the home (improving dim lighting, installing non-slip mats, installing stair handrails, etc.), muscle-strengthening exercise, and balance training are recommended. In patients at high risk of falls, the indication for anticoagulants and the fall risk are reassessed to decide the direction of treatment. Stopping alcohol abuse contributes to recovery of coagulation function, increased platelet production, and reduced fall risk, and is effective in preventing nontraumatic subdural hematoma.
To prevent subdural hematoma related to intracranial hypotension, appropriate CSF collection volumes should be observed during lumbar puncture, and adequate fluid intake and rest are recommended after lumbar puncture. In groups at high risk of recurrent spontaneous intracranial hypotension, accurately identifying the site of CSF leakage and providing definitive treatment with an epidural blood patch or surgical repair are important for preventing recurrence. Early endovascular treatment or radiosurgery for high-risk forms of dural arteriovenous fistula (cortical venous reflux) contributes to the prevention of hemorrhagic subdural hematoma.
Adhiyaman V, Asghar M, Ganeshram KN, Bhowmick BK. Chronic subdural haematoma in the elderly. Postgrad Med J. 2002;78(916):71-75. DOI: 10.1136/pmj.78.916.71. PMID: 11807187.
Kudo H, Kuwamura K, Izawa I, Sawa H, Tamaki N. Chronic subdural hematoma in elderly people: present status on Awaji Island and epidemiological prospect. Neurol Med Chir (Tokyo). 1992;32(4):207-209. DOI: 10.2176/nmc.32.207. PMID: 1377999.
Almenawer SA, Farrokhyar F, Hong C, et al. Chronic subdural hematoma management: a systematic review and meta-analysis of 34,829 patients. Ann Surg. 2014;259(3):449-457. DOI: 10.1097/SLA.0000000000000255. PMID: 23979272.
Brennan PM, Kolias AG, Joannides AJ, et al. The management and outcome for patients with chronic subdural hematoma: a prospective, multicenter, observational cohort study in the United Kingdom. J Neurosurg. 2017;127(4):732-739. DOI: 10.3171/2016.8.JNS16134. PMID: 27834599.
Dran G, Berthier F, Fontaine D, Rasenrarijao D, Paquis P. Effective treatment of chronic subdural hematoma by burr-hole craniostomy and closed-system drainage under local anesthesia: a prospective study of 148 patients. Neurochirurgie. 2007;53(1):18-27. DOI: 10.1016/j.neuchi.2006.11.007. PMID: 17337274.
Link TW, Boddu S, Paine SM, Kamel H, Knopman J. Middle meningeal artery embolization for chronic subdural hematoma: a series of 60 cases. Neurosurgery. 2019;85(6):801-807. DOI: 10.1093/neuros/nyy521. PMID: 30452695.
Frati A, Salvati M, Mainiero F, et al. Inflammation markers and risk factors for recurrence in 35 patients with a posttraumatic chronic subdural hematoma: a prospective study. J Neurosurg. 2004;100(1):24-32. DOI: 10.3171/jns.2004.100.1.0024. PMID: 14743907.
Rust T, Kiemer N, Erasmus A. Chronic subdural haematomas and anticoagulation or anti-thrombotic therapy. J Clin Neurosci. 2006;13(8):823-827. DOI: 10.1016/j.jocn.2004.12.013. PMID: 16996747.
Higgins T, Jolley C, Crooks A, et al. Epidemiology of spontaneous intracranial subdural haemorrhage: a population-based study. Br J Neurosurg. 2020;34(3):312-317. DOI: 10.1080/02688697.2019.1683532. PMID: 31661329.
Schievink WI. Spontaneous spinal cerebrospinal fluid leaks and intracranial hypotension. JAMA. 2006;295(19):2286-2296. DOI: 10.1001/jama.295.19.2286. PMID: 16705110.